FHIT and cervical cancer: Cervical cancer was the first to be assessed for Fhit protein expression by immunohistochemistry and Fhit loss or reduction was observed in ∼70% of cervical cancers, a loss that correlated with the detection of aberrant FHIT RT–PCR amplification products.